MX2017006464A - Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. - Google Patents

Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.

Info

Publication number
MX2017006464A
MX2017006464A MX2017006464A MX2017006464A MX2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A MX 2017006464 A MX2017006464 A MX 2017006464A
Authority
MX
Mexico
Prior art keywords
inhibitor
bruton
tyrosine kinase
tlr
combinations
Prior art date
Application number
MX2017006464A
Other languages
English (en)
Inventor
Y Chang Betty
Kuo Hsu-Ping
Beaupre Darrin
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of MX2017006464A publication Critical patent/MX2017006464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se proveen composiciones y métodos para tratar neoplasias malignas de linfocitos B en un sujeto que lo necesita mediante la administración al sujeto de una cantidad terapéuticamente eficaz de una combinación que comprende un inhibidor de un inhibidor de BTK y un inhibidor de TLR.
MX2017006464A 2014-11-17 2015-11-17 Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. MX2017006464A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080921P 2014-11-17 2014-11-17
US201562127740P 2015-03-03 2015-03-03
PCT/US2015/061091 WO2016081460A1 (en) 2014-11-17 2015-11-17 Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations

Publications (1)

Publication Number Publication Date
MX2017006464A true MX2017006464A (es) 2018-08-09

Family

ID=56014455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006464A MX2017006464A (es) 2014-11-17 2015-11-17 Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.

Country Status (11)

Country Link
US (1) US20170354655A1 (es)
EP (1) EP3220912A4 (es)
JP (1) JP2017533944A (es)
CN (1) CN106999495A (es)
AU (1) AU2015350136A1 (es)
BR (1) BR112017010262A2 (es)
CA (1) CA2966542A1 (es)
HK (1) HK1243929A1 (es)
MX (1) MX2017006464A (es)
TW (1) TW201628622A (es)
WO (1) WO2016081460A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2419610C2 (ru) 2005-05-26 2011-05-27 Ньюрон Системз, Инк. Композиции и способы лечения заболевания сетчатки
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
MX2015009383A (es) 2013-01-23 2016-03-17 Aldeyra Therapeutics Inc Enfermedades relacionadas con aldehido toxico y tratamiento.
CA3077362A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
CN110272417B (zh) * 2019-06-18 2021-07-13 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用
CN110305128B (zh) * 2019-07-31 2021-08-24 桂林医学院 5-氨基苯并[b][1,8]萘啶类化合物的制备方法和应用
JP2023526016A (ja) * 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2571530A4 (en) * 2010-05-20 2014-03-05 Univ Rochester METHOD AND COMPOSITIONS FOR AUTOPHAGIA MODULATION
CA3154024C (en) * 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
US20140206681A1 (en) * 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
CN105073115A (zh) * 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
CN111317821A (zh) * 2013-04-08 2020-06-23 药品循环有限责任公司 依鲁替尼联合疗法

Also Published As

Publication number Publication date
WO2016081460A1 (en) 2016-05-26
EP3220912A1 (en) 2017-09-27
JP2017533944A (ja) 2017-11-16
CA2966542A1 (en) 2016-05-26
US20170354655A1 (en) 2017-12-14
HK1243929A1 (zh) 2018-07-27
TW201628622A (zh) 2016-08-16
AU2015350136A1 (en) 2017-05-25
BR112017010262A2 (pt) 2018-07-03
EP3220912A4 (en) 2018-06-20
CN106999495A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX2017001656A (es) Combinaciones de inhibidor de tirosina cinasa de bruton y usos de estas.
MD4733C1 (ro) Anticorpi anti-TIGIT
MX2016014248A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2017002388A (es) Composiciones para fibras de queratina.
MX2017000306A (es) Metodos para tratar hipotension.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2019000677A (es) Células miméticas de células b.